These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 28515147)

  • 1. Increased T-cell Infiltration Elicited by
    Loveridge CJ; Mui EJ; Patel R; Tan EH; Ahmad I; Welsh M; Galbraith J; Hedley A; Nixon C; Blyth K; Sansom O; Leung HY
    Cancer Res; 2017 Jun; 77(12):3158-3168. PubMed ID: 28515147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concomitant loss of EAF2/U19 and Pten synergistically promotes prostate carcinogenesis in the mouse model.
    Ai J; Pascal LE; O'Malley KJ; Dar JA; Isharwal S; Qiao Z; Ren B; Rigatti LH; Dhir R; Xiao W; Nelson JB; Wang Z
    Oncogene; 2014 May; 33(18):2286-94. PubMed ID: 23708662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PTEN-deficient prostate cancer is associated with an immunosuppressive tumor microenvironment mediated by increased expression of IDO1 and infiltrating FoxP3+ T regulatory cells.
    Vidotto T; Saggioro FP; Jamaspishvili T; Chesca DL; Picanço de Albuquerque CG; Reis RB; Graham CH; Berman DM; Siemens DR; Squire JA; Koti M
    Prostate; 2019 Jun; 79(9):969-979. PubMed ID: 30999388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor heterogeneity, aggressiveness, and immune cell composition in a novel syngeneic PSA-targeted Pten knockout mouse prostate cancer (MuCaP) model.
    van Duijn PW; Marques RB; Ziel-van der Made ACJ; van Zoggel HJAA; Aghai A; Berrevoets C; Debets R; Jenster G; Trapman J; van Weerden WM
    Prostate; 2018 Sep; 78(13):1013-1023. PubMed ID: 30133757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteomic and transcriptomic profiling of Pten gene-knockout mouse model of prostate cancer.
    Zhang J; Kim S; Li L; Kemp CJ; Jiang C; Lü J
    Prostate; 2020 May; 80(7):588-605. PubMed ID: 32162714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potentiation of inflammatory CXCL8 signalling sustains cell survival in PTEN-deficient prostate carcinoma.
    Maxwell PJ; Coulter J; Walker SM; McKechnie M; Neisen J; McCabe N; Kennedy RD; Salto-Tellez M; Albanese C; Waugh DJ
    Eur Urol; 2013 Aug; 64(2):177-88. PubMed ID: 22939387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In situ vaccination combined with androgen ablation and regulatory T-cell depletion reduces castration-resistant tumor burden in prostate-specific pten knockout mice.
    Akins EJ; Moore ML; Tang S; Willingham MC; Tooze JA; Dubey P
    Cancer Res; 2010 May; 70(9):3473-82. PubMed ID: 20406970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Timp3 loss accelerates tumour invasion and increases prostate inflammation in a mouse model of prostate cancer.
    Adissu HA; McKerlie C; Di Grappa M; Waterhouse P; Xu Q; Fang H; Khokha R; Wood GA
    Prostate; 2015 Dec; 75(16):1831-43. PubMed ID: 26332574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by intermittent anti-PI3Kα/β/δ treatment.
    Qi Z; Xu Z; Zhang L; Zou Y; Li J; Yan W; Li C; Liu N; Wu H
    Nat Commun; 2022 Jan; 13(1):182. PubMed ID: 35013322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chromatin Regulator CHD1 Remodels the Immunosuppressive Tumor Microenvironment in PTEN-Deficient Prostate Cancer.
    Zhao D; Cai L; Lu X; Liang X; Li J; Chen P; Ittmann M; Shang X; Jiang S; Li H; Meng C; Flores I; Song JH; Horner JW; Lan Z; Wu CJ; Li J; Chang Q; Chen KC; Wang G; Deng P; Spring DJ; Wang YA; DePinho RA
    Cancer Discov; 2020 Sep; 10(9):1374-1387. PubMed ID: 32385075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multi-faceted immunomodulatory and tissue-tropic clinical bacterial isolate potentiates prostate cancer immunotherapy.
    Anker JF; Naseem AF; Mok H; Schaeffer AJ; Abdulkadir SA; Thumbikat P
    Nat Commun; 2018 Apr; 9(1):1591. PubMed ID: 29686284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The transcription factor FOXF1 promotes prostate cancer by stimulating the mitogen-activated protein kinase ERK5.
    Fulford L; Milewski D; Ustiyan V; Ravishankar N; Cai Y; Le T; Masineni S; Kasper S; Aronow B; Kalinichenko VV; Kalin TV
    Sci Signal; 2016 May; 9(427):ra48. PubMed ID: 27165781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of Nkx3.1 leads to the activation of discrete downstream target genes during prostate tumorigenesis.
    Song H; Zhang B; Watson MA; Humphrey PA; Lim H; Milbrandt J
    Oncogene; 2009 Sep; 28(37):3307-19. PubMed ID: 19597465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD4
    Liu S; Liu F; Zhang B; Yan P; Rowan BG; Abdel-Mageed AB; Steele C; Jazwinski SM; Moroz K; Norton EB; Wang A; Myers L; Sartor O; Zhang Q
    Prostate; 2020 Jul; 80(10):764-776. PubMed ID: 32356608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Slow disease progression in a C57BL/6 pten-deficient mouse model of prostate cancer.
    Svensson RU; Haverkamp JM; Thedens DR; Cohen MB; Ratliff TL; Henry MD
    Am J Pathol; 2011 Jul; 179(1):502-12. PubMed ID: 21703427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRF1 accelerates prostate tumourigenesis and perturbs immune infiltration.
    Loveridge CJ; Slater S; Campbell KJ; Nam NA; Knight J; Ahmad I; Hedley A; Lilla S; Repiscak P; Patel R; Salji M; Fleming J; Mitchell L; Nixon C; Strathdee D; Neilson M; Ntala C; Bryson S; Zanivan S; Edwards J; Robson CN; Goodyear CS; Blyth K; Leung HY
    Oncogene; 2020 Feb; 39(8):1797-1806. PubMed ID: 31740786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction of the Androgen Receptor, ETV1, and PTEN Pathways in Mouse Prostate Varies with Pathological Stage and Predicts Cancer Progression.
    Higgins J; Brogley M; Palanisamy N; Mehra R; Ittmann MM; Li JZ; Tomlins SA; Robins DM
    Horm Cancer; 2015 Jun; 6(2-3):67-86. PubMed ID: 25631336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infiltrating CD4+ T cells attenuate chemotherapy sensitivity in prostate cancer via CCL5 signaling.
    Xiang P; Jin S; Yang Y; Sheng J; He Q; Song Y; Yu W; Hu S; Jin J
    Prostate; 2019 Jun; 79(9):1018-1031. PubMed ID: 31018021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diverse genetic-driven immune landscapes dictate tumor progression through distinct mechanisms.
    Bezzi M; Seitzer N; Ishikawa T; Reschke M; Chen M; Wang G; Mitchell C; Ng C; Katon J; Lunardi A; Signoretti S; Clohessy JG; Zhang J; Pandolfi PP
    Nat Med; 2018 Feb; 24(2):165-175. PubMed ID: 29309058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pten null prostate epithelium promotes localized myeloid-derived suppressor cell expansion and immune suppression during tumor initiation and progression.
    Garcia AJ; Ruscetti M; Arenzana TL; Tran LM; Bianci-Frias D; Sybert E; Priceman SJ; Wu L; Nelson PS; Smale ST; Wu H
    Mol Cell Biol; 2014 Jun; 34(11):2017-28. PubMed ID: 24662052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.